selectION, Inc. Initiates Dosing in Atopic Dermatitis Patients
Phase 1b trial is designed to evaluate safety, tolerability, and efficacy of potent Kv1.3 blocker in T-cell mediated autoimmunity – San Diego, CA, USA, and Munich, Germany – September 12,…
Read More